Tex.
Ins. Code Section 1372.001
Definitions
(1)
“Biomarker” means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention. The term includes:(A)
gene mutations; and(B)
protein expression.(2)
“Biomarker testing” means the analysis of a patient’s tissue, blood, or other biospecimen for the presence of a biomarker. The term includes:(A)
single-analyte tests;(B)
multiplex panel tests; and(C)
whole genome sequencing.(3)
“Consensus statements” means statements that:(A)
address specific clinical circumstances based on the best available evidence for the purpose of optimizing clinical care outcomes; and(B)
are developed by an independent, multidisciplinary panel of experts that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy.(4)
“Nationally recognized clinical practice guidelines” means evidence-based clinical practice guidelines that:(A)
establish a standard of care informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options;(B)
include recommendations intended to optimize patient care; and(C)
are developed by an independent organization or medical professional society that uses a transparent methodology and reporting structure and is subject to a conflict of interest policy.
Source:
Section 1372.001 — Definitions, https://statutes.capitol.texas.gov/Docs/IN/htm/IN.1372.htm#1372.001 (accessed May 4, 2024).
